Reminyl is available by prescription in 4 mg, 8 mg or 12 mg tablets, as well as in an oral solution (4mg/ml). It should be taken by patients twice a day, preferably with morning and evening meals. It is recommended that physicians start by prescribing 8 mg of Reminyl per day (in two divided doses) for at least four weeks, then increase to the recommended maintenance dose of 16 mg per day. Physicians have the flexibility to increase the daily dose to 24 mg after an additional four weeks. More information on the product, including full prescribing information, can be found at www.reminyl.com.

About Reminyl

Reminyl was first approved in Sweden in March of 2000, for the treatment of mild to moderate Alzheimers disease. It is believed that Reminyl inhibits an enzyme that breaks down acetylcholine a chemical in the brain that plays a key role in memory and learning. It also is believed that Reminyl modulates the brains nicotinic receptors, to which acetylcholine binds. Laboratory research suggests that through this modulation, Reminyl stimulates greater release of acetylcholine. Research designed to define the significance of this finding in humans is underway.

'"/>

Contact: Andrew Cooper
andrew.cooper@ketchum.com
44-020-7611-3859
Ketchum
13-Sep-2001